Study Of the Safety of Locally Manufactured 123I-metaiodobenzylguanidine(MIBG) in Routine Clinical Use

NCT01912040 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-11-14

No results posted yet for this study

Summary

Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.

Conditions

  • Adrenergic Pathology

Interventions

DRUG

Administration of 123Iodine MIBG

Patients will be administered the locally produced 123 Iodine MIBG

Sponsors & Collaborators

  • Nova Scotia Health Authority

    lead OTHER

Principal Investigators

  • Andrew Ross, MD · Division Head, Nuclear Medicine

Eligibility

Min Age
1 Month
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01912040 on ClinicalTrials.gov